Finnish drugmaker Orion on Wednesday raised its full-year 2025 forecast, citing stronger-than-expected product sales and royalty income.
The company now expects net sales of between 1.63 billion and 1.73 billion euros, up from a previous estimate of 1.55 billion to 1.65 billion euros.
Operating profit is now projected to be between 400 million and 500 million euros, compared with an earlier forecast of 350 million to 450 million euros.
According to the company, the upgrade is due to sales and royalty income increasing faster than anticipated in the first half of the year, a trend it expects to continue.
The improved outlook follows recent regulatory successes for its blockbuster prostate cancer drug Nubeqa, which it develops with partner Bayer.
The treatment recently gained a key U.S. approval and a positive recommendation from a European panel for an expanded use in treating metastatic hormone-sensitive prostate cancer.
Orion said the new forecast does not include a potential 180 million euro milestone payment from Bayer for Nubeqa sales, citing uncertainty over the timing of the payment which could come in 2025 or 2026.
More from this issuer
Related coverage
Orion has secured an exclusive license for an experimental cancer antibody from Abzena, the latest in a series of deals to strengthen its oncology pipeline following a recent clinical trial failure.
Finnish drugmaker Orion Corp. said Tuesday its experimental insomnia drug failed a mid-stage clinical trial, days after investment giant BlackRock Inc. cut its stake in the company.
Orion and its partner Bayer have secured European Union approval for an expanded use of their blockbuster prostate cancer drug, Nubeqa, the latest in a series of regulatory wins for the treatment.
Orion Corp. reported a 59% surge in second-quarter operating profit, driven by strong sales and royalty income from its blockbuster prostate cancer drug, Nubeqa.